Retail Investors Rush to Novo Nordisk Amid Disappointing Drug Data
Retail investors are turning their attention to Novo Nordisk following underwhelming results from its weight-loss drug. Explore the healthcare investment trend.
Retail investors flock to Novo Nordisk after weight-loss drug data disappoints.